Angiotensin Receptor Antagonists

"Angiotensin Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR.

Descriptor ID	D057911
MeSH Number(s)	D27.505.519.162
Concept/Terms	Angiotensin Receptor Antagonists Angiotensin Receptor Antagonists Antagonists, Angiotensin Receptor Receptor Antagonists, Angiotensin Angiotensin Receptor Blockers Receptor Blockers, Angiotensin Angiotensin II Receptor Antagonists Angiotensin II Receptor Antagonists Angiotensin II Receptor Blockers

Below are MeSH descriptors whose meaning is more general than "Angiotensin Receptor Antagonists".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Angiotensin Receptor Antagonists [D27.505.519.162]

Below are MeSH descriptors whose meaning is more specific than "Angiotensin Receptor Antagonists".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Angiotensin Receptor Antagonists" by people in this website by year, and whether "Angiotensin Receptor Antagonists" was a major or minor topic of these publications.

Bar chart showing 38 publications over 17 distinct years, with a maximum of 5 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2008	1	1	2
2009	0	1	1
2010	0	1	1
2011	1	1	2
2012	1	0	1
2013	2	0	2
2014	2	0	2
2015	2	1	3
2016	1	2	3
2017	2	0	2
2018	1	0	1
2019	1	2	3
2020	3	1	4
2021	2	2	4
2022	2	3	5
2023	0	1	1
2024	0	1	1

Below are the most recent publications written about "Angiotensin Receptor Antagonists" by people in Profiles.

Sevre K, Rist A, Wachtell K, Devereux RB, Aurigemma GP, Smiseth OA, Kjeldsen SE, Julius S, Pitt B, Burnier M, Kreutz R, Oparil S, Mancia G, Zannad F. What Is the Current Best Drug Treatment for Hypertensive Heart Failure With Preserved Ejection Fraction? Review of the Totality of Evidence. Am J Hypertens. 2024 01 01; 37(1):1-14.

View in: PubMed
Rist A, Sevre K, Wachtell K, Devereux RB, Aurigemma GP, Smiseth OA, Kjeldsen SE, Julius S, Pitt B, Burnier M, Kreutz R, Oparil S, Mancia G, Zannad F. The current best drug treatment for hypertensive heart failure with preserved ejection fraction. Eur J Intern Med. 2024 Feb; 120:3-10.

View in: PubMed
Tisminetzky M, Gurwitz JH, Tabada G, Reynolds K, Fortmann SP, Garcia E, Pham T, Goldberg R, Go AS. Adverse Events After Initiating Angiotensin-Converting Enzyme Inhibitor/Angiotensin II Receptor Blocker Therapy in Individuals with Heart Failure and Multimorbidity. Am J Med. 2022 12; 135(12):1468-1477.

View in: PubMed
Gupta N, Settle L, Brown BR, Armaignac DL, Baram M, Perkins NE, Kaufman M, Melamed RR, Christie AB, Danesh VC, Denson JL, Cheruku SR, Boman K, Bansal V, Kumar VK, Walkey AJ, Domecq JP, Kashyap R, Aston CE. Association of Renin Angiotensin Aldosterone System Inhibitors and Outcomes of Hospitalized Patients With COVID-19. Crit Care Med. 2022 10 01; 50(10):e744-e758.

View in: PubMed
Gabot A, Lavitas P, Bacon R, Pomfret TC, Taylor M, Coelho A, Greenwood BC, Alper CJ, Clements KM, Lenz K. Cost-benefit analysis of sacubitril/valsartan in a Medicaid population. Am J Manag Care. 2022 07; 28(7):349-352.

View in: PubMed
Keith SW, Maio V, Arafat HA, Alcusky M, Karagiannis T, Rabinowitz C, Lavu H, Louis DZ. Angiotensin blockade therapy and survival in pancreatic cancer: a population study. BMC Cancer. 2022 Feb 07; 22(1):150.

View in: PubMed
Mann DL, Givertz MM, Vader JM, Starling RC, Shah P, McNulty SE, Anstrom KJ, Margulies KB, Kiernan MS, Mahr C, Gupta D, Redfield MM, Lala A, Lewis GD, DeVore AD, Desvigne-Nickens P, Hernandez AF, Braunwald E. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA Cardiol. 2022 01 01; 7(1):17-25.

View in: PubMed
Rattanapunya S, Deethae A, Woskie S, Kongthip P, Matthews KR. Occurrence of Antibiotic-Resistant Staphylococcus spp. in Orange Orchards in Thailand. Int J Environ Res Public Health. 2021 12 27; 19(1).

View in: PubMed
Brinkley DM, Wang L, Yu C, Grandin EW, Kiernan MS. Impact of renin-angiotensin-aldosterone system inhibition on morbidity and mortality during long-term continuous-flow left ventricular assist device support: An IMACS report. J Heart Lung Transplant. 2021 12; 40(12):1605-1613.

View in: PubMed
Kim YS, Brar S, D'Albo N, Dey A, Shah S, Ganatra S, Dani SS. Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance. Cardiovasc Drugs Ther. 2022 10; 36(5):915-924.

View in: PubMed

People

Explore

Similar Concepts

Top Journals